Original Article: Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy (phase 3 SAFFRON trial) https://nej.md/4hXdueb

NEJM· @NEJM · X·2026-10-26 23:00· 7 小时前评分70

正文 · 原文

#ESMO26 | @myESMO

1084 浏览 · 4 赞 · 0 转发 · 0 回复

来源：NEJM · x.com